Process Chemistry: Lab to Pilot in 5 Stages

Why Process Chemistry Matters: The Cost of Getting It Wrong

Before examining the five stages, it is worth understanding why process chemistry optimization commands such significant investment — and what happens when organizations try to skip or shortcut the process.

The most common failure mode is attempting to scale a medicinal chemistry route directly to production. Medicinal chemistry routes are designed for speed and flexibility, not for manufacturing efficiency. They frequently use expensive reagents (palladium catalysts at 5-10 mol%), require chromatographic purification at multiple steps, employ solvents that are problematic at scale (dichloromethane, diethyl ether), and tolerate low yields because only milligrams of product are needed.

The consequences of scaling an unoptimized route include:

• Cost inflation: A medicinal chemistry route producing material at $5,000 per gram at laboratory scale may cost $500-$2,000 per gram at kilogram scale if the route has not been optimized. A properly optimized process for the same compound might cost $50-$200 per gram — a 10x to 40x cost reduction. Working with a custom synthesis partner experienced in process development avoids this trap.
• Safety incidents: Exothermic reactions that are easily managed in a 50-mL flask can generate dangerous quantities of heat at 500-liter scale. The 2007 T2 Laboratories explosion in Jacksonville, Florida — which killed four workers — resulted from inadequate understanding of a runaway exothermic reaction during scale-up of a methylcyclopentadienyl manganese tricarbonyl process.
• Regulatory delays: Processes that are not adequately characterized and controlled generate variable impurity profiles, inconsistent yields, and incomplete process understanding — all of which trigger regulatory questions and requests for additional data that delay IND and NDA approvals.
• Supply chain disruption: Processes dependent on single-source or expensive starting materials create supply vulnerabilities that can halt production when a supplier has quality issues or exits the market.

The investment in proper process chemistry optimization — typically $200,000 to $1,000,000 over 6-18 months — routinely saves organizations millions of dollars over the product lifecycle while reducing safety risk, regulatory risk, and supply chain risk.

Stage 1: Route Selection and Retrosynthetic Analysis

The first and most consequential stage of process chemistry optimization is selecting the synthetic route that will carry the compound from laboratory to commercial production. A route change after pilot-plant investment has been made can cost $500,000 to $2,000,000 in direct expenses and delay programs by 12-24 months. Getting the route right at the outset is the highest-leverage decision in the entire development process.

Retrosynthetic Analysis for Manufacturability

Process-oriented retrosynthetic analysis differs from academic retrosynthesis in its evaluation criteria. Academic retrosynthesis prioritizes elegance, novelty, and step economy. Process retrosynthesis prioritizes:

• Starting material availability and cost: Preferred routes begin from starting materials available from multiple suppliers at commodity or near-commodity prices. A starting material costing $50/kg from three suppliers is vastly preferable to one costing $500/kg from a single source, even if the latter enables a shorter route.
• Reaction scalability: Each reaction in the route must be evaluated for its behavior at large scale. Reactions requiring precise temperature control within narrow ranges (e.g., lithiation reactions at -78 degrees C) are expensive to implement at scale due to cryogenic equipment requirements. Reactions generating gases (diazotization, Curtius rearrangement) require engineered venting systems.
• Purification feasibility: Chromatographic purification is generally impractical above kilogram scale due to solvent consumption and throughput limitations. Preferred routes incorporate reactions where products can be isolated by crystallization, filtration, extraction, or distillation.
• Solvent and reagent selection: ICH Q3C classifies solvents into three categories: Class 1 (to be avoided — benzene, carbon tetrachloride), Class 2 (limited use — dichloromethane, DMF, NMP), and Class 3 (low toxic potential — ethanol, acetone, ethyl acetate, heptane). Process routes should favor Class 3 solvents wherever possible. Similarly, reagents should be selected for safety, cost, and waste stream compatibility.
• Convergent vs. linear strategy: Convergent routes (where two or more fragments are synthesized independently and then joined) are generally preferred over linear routes (where each step builds sequentially on the previous product) because convergent routes produce higher overall yields, allow parallel execution of fragment syntheses, and localize the impact of a failed reaction to one fragment rather than the entire sequence.

Route Scoring and Selection

A structured route evaluation typically scores 3-5 candidate routes against weighted criteria:

Criterion	Weight	Route A Score	Route B Score	Route C Score
Step count (fewer is better)	15%	8/10 (5 steps)	6/10 (7 steps)	7/10 (6 steps)
Overall predicted yield	15%	7/10 (32%)	5/10 (18%)	8/10 (38%)
Starting material cost/availability	20%	9/10	6/10	7/10
Scalability of key reactions	20%	7/10	8/10	6/10
Purification feasibility	15%	8/10	5/10	7/10
Safety profile	10%	7/10	7/10	9/10
Freedom-to-operate (IP)	5%	8/10	9/10	6/10
Weighted total	100%	7.6	6.3	7.2

In this example, Route A scores highest overall, driven by strong starting material economics and purification feasibility. Route C offers the best yield and safety profile but is weaker on scalability. Route B, despite having strong scalability scores, is penalized by its longer step count and reliance on chromatographic purification.

Timeline and Cost for Stage 1

Route selection and retrosynthetic analysis typically requires 2-6 weeks and costs $15,000-$50,000. This includes literature and patent searching, computational route analysis, route scoring, and a recommendation report. For complex molecules with limited precedent, the timeline may extend to 8-12 weeks if experimental feasibility studies are needed to validate key transformations.

Stage 2: Reaction Optimization

Once a lead route is selected, each reaction step must be individually optimized for yield, selectivity, robustness, and reproducibility. This is where process chemistry transitions from strategic analysis to hands-on experimental work.

Design of Experiments (DoE)

Modern reaction optimization relies heavily on statistical Design of Experiments (DoE) methodology rather than traditional one-variable-at-a-time (OVAT) approaches. DoE systematically varies multiple parameters simultaneously, extracting maximum information from minimum experiments and revealing interaction effects that OVAT misses.

A typical DoE campaign for a single reaction step involves:

1. Factor identification: Select 4-8 factors to investigate — temperature, reagent stoichiometry, solvent composition, catalyst loading, concentration, addition rate, reaction time, and order of addition
2. Screening design (fractional factorial or Plackett-Burman): Run 12-24 experiments to identify which factors have statistically significant effects on the response variables (yield, purity, impurity formation)
3. Optimization design (central composite or Box-Behnken): Run 15-30 experiments focusing on the significant factors identified in screening, mapping the response surface to identify the optimal operating region
4. Verification runs: Execute 3-5 runs at the predicted optimal conditions to confirm that the model accurately predicts actual performance

A DoE campaign for a single reaction step typically requires 2-4 weeks of laboratory time and generates a mathematical model that predicts process performance across the investigated parameter space. This model becomes the foundation for defining proven acceptable ranges (PARs) in regulatory submissions.

Solvent Screening

Solvent selection affects reaction yield, selectivity, impurity profile, product isolation, and environmental impact. A systematic solvent screen evaluates 8-15 solvents (or solvent mixtures) for each key reaction step, assessing:

• Reaction performance: Yield and selectivity in each solvent system
• Product solubility: Solubility in the reaction solvent (high enough for reasonable concentration) and in the anti-solvent used for crystallization (low enough for good recovery)
• Impurity behavior: Some impurities may form preferentially in certain solvents due to competing reaction pathways or solvent participation
• Practical considerations: Boiling point (affects distillation and workup), water miscibility (affects aqueous extraction), and flammability (affects safety engineering)
• Regulatory classification: ICH Q3C classification and permitted daily exposure limits
• Environmental impact: E-factor contribution, recyclability, and waste treatment requirements

A concrete example: replacing dichloromethane (ICH Class 2, PDE 6 mg/day, ozone-depleting) with 2-methyltetrahydrofuran (ICH Class 3, readily biodegradable, derived from renewable resources) in an extraction step eliminates a regulatory liability, reduces waste treatment costs, and may even improve partition coefficients for certain compound types.

Catalyst Selection and Optimization

For reactions involving catalysis — cross-coupling reactions (Suzuki, Heck, Buchwald-Hartwig), hydrogenations, asymmetric transformations — catalyst selection profoundly impacts process economics and product quality.

Key optimization parameters include:

• Catalyst loading: Reducing palladium loading from 5 mol% (typical medicinal chemistry) to 0.1-0.5 mol% (typical process chemistry) can reduce catalyst costs by 90-98%. This requires screening more active catalyst systems (e.g., Pd-XPhos, Pd-SPhos, or Pd-PEPPSI complexes) and optimizing reaction conditions for turnover.
• Ligand selection: The choice of phosphine or NHC ligand controls catalyst activity, selectivity, and stability. Bulky, electron-rich ligands (XPhos, RuPhos, BrettPhos) enable couplings at lower catalyst loadings and with broader substrate tolerance.
• Residual metal control: ICH Q3D limits for palladium in oral drug products are 10 ppm. Achieving this limit requires either very low catalyst loading, effective scavenging (activated carbon, thiol-functionalized silica, Smopex scavengers), or both. Residual metal removal adds cost and should be designed into the process rather than addressed as an afterthought. Our guide to impurity profiling and forced degradation covers ICH Q3D requirements in detail.
• Heterogeneous vs. homogeneous catalysis: Heterogeneous catalysts (Pd/C, Pd/Al2O3) are easier to remove by filtration but may offer lower activity or selectivity. Homogeneous catalysts offer superior performance but require scavenging or crystallization-based purge to meet metal limits.

Real-World Example: Yield Optimization

Consider a Suzuki-Miyaura coupling in a kinase inhibitor synthesis:

• Medicinal chemistry conditions: 5 mol% Pd(PPh3)4, 3 eq K2CO3, DMF/H2O 4:1, 100 degrees C, 16 hours. Yield: 65%. Purification: column chromatography.
• After DoE optimization: 0.3 mol% Pd(OAc)2/SPhos, 1.5 eq K3PO4, THF/H2O 9:1, 70 degrees C, 4 hours. Yield: 92%. Purification: direct crystallization from IPA/heptane.

The optimized conditions reduced catalyst cost by 94%, eliminated chromatography, increased yield by 27 percentage points, and shortened reaction time by 75%. Applied to a 50-kg production campaign, these improvements saved approximately $180,000 in catalyst costs alone, plus an estimated $60,000 in purification costs and 3 weeks of production time.

Timeline and Cost for Stage 2

Reaction optimization across a typical 5-7 step synthesis requires 2-4 months of laboratory work and costs $80,000-$250,000. The investment scales roughly linearly with step count, with additional cost for steps involving catalysis, chiral resolution, or complex workup procedures.

Stage 3: Process Safety Assessment

Process safety assessment is not optional — it is a regulatory requirement, an ethical imperative, and, when done properly, a source of valuable process understanding that improves control and reduces risk.

Thermal Screening

Every reaction and intermediate in the process must be evaluated for thermal stability and exothermic potential. The standard progression of thermal testing is:

1. DSC (Differential Scanning Calorimetry): A rapid screening technique that heats a small sample (2-10 mg) at a defined rate and measures heat flow. DSC identifies exothermic events (decomposition, crystallization, chemical reaction) and their onset temperatures. Any intermediate with a DSC exotherm onset below 100 degrees C above the maximum process temperature requires further evaluation.

2. ARC (Accelerating Rate Calorimetry): An adiabatic calorimetry technique that detects self-heating behavior in larger samples (1-5 g). ARC measures the temperature and pressure rise that would occur if a material were thermally isolated (as it might be in a large reactor with failed cooling). ARC data determines the Time to Maximum Rate (TMR) — the time from onset of self-heating to thermal runaway at a given temperature — which is the key metric for defining safe process operating windows.

3. RC1 (Reaction Calorimetry): A bench-scale reactor (typically 500 mL-2 L) equipped with precise heat flow measurement that characterizes the thermal behavior of actual reactions under process conditions. RC1 experiments determine the total heat of reaction (kJ/mol), the maximum heat generation rate (W/kg), the adiabatic temperature rise if cooling fails, and the heat accumulation during reagent addition.

DIERS Testing and Vent Sizing

For reactions identified as potentially hazardous by screening calorimetry, the Design Institute for Emergency Relief Systems (DIERS) methodology determines the emergency venting requirements for the production reactor. DIERS testing uses specialized equipment (VSP2, PHI-TEC) to simulate runaway scenarios and measure:

• Maximum temperature and pressure during runaway
• Rate of pressure rise (dP/dt) at maximum
• Two-phase flow characteristics (vapor-only vs. vapor-liquid mixture venting)
• Required vent area to prevent reactor overpressurization

This data feeds directly into the engineering design of the pilot plant reactor’s pressure relief system — a critical safety system that must be sized correctly before any scale-up work begins.

Hazard Classification

Every chemical used or produced in the process must be classified according to the Globally Harmonized System (GHS) for hazard communication:

• Physical hazards: Flammability, oxidizing potential, self-reactivity, organic peroxide formation, corrosivity, explosivity
• Health hazards: Acute toxicity, skin/eye irritation, sensitization, mutagenicity, carcinogenicity, reproductive toxicity, specific target organ toxicity
• Environmental hazards: Aquatic toxicity, persistence, bioaccumulation potential

Hazard classifications determine personal protective equipment requirements, engineering controls (containment levels, ventilation), storage requirements, transportation regulations, and waste handling procedures. For pharmaceutical applications, compounds with occupational exposure bands (OEBs) at Category 4 or 5 (OEL <1 microgram/m3 for Category 5) require containment engineering that significantly impacts facility design and operating costs.

Process Hazard Analysis

Before executing any process at pilot scale, a formal Process Hazard Analysis (PHA) should be conducted. The most common methodology is HAZOP (Hazard and Operability Study), which systematically examines each process step by applying guide words (more, less, no, reverse, other) to each process parameter (temperature, pressure, flow, concentration, time) to identify potential deviations, their consequences, and the safeguards required to prevent or mitigate them.

A typical HAZOP for a 5-7 step synthesis requires 2-3 days of team meetings involving process chemists, chemical engineers, safety professionals, and operations personnel. The output is a documented set of action items — engineering controls, procedural safeguards, and instrumentation requirements — that must be implemented before the pilot campaign begins.

Timeline and Cost for Stage 3

Process safety assessment for a typical multi-step synthesis requires 4-8 weeks and costs $30,000-$100,000. The range reflects the number of reactions and intermediates requiring evaluation and whether DIERS testing or specialized hazard studies (dust explosion testing for powdered intermediates, static sensitivity testing) are needed. This investment is non-negotiable — the cost of a safety incident, in human, legal, and financial terms, is orders of magnitude greater.

Stage 4: Pilot Plant Design and Execution

The pilot plant campaign is where optimized laboratory chemistry meets real-world engineering constraints. This stage translates bench-scale procedures into equipment-specific batch records and demonstrates that the process performs at scale as predicted by laboratory development.

Kilo-Lab Operations (1-10 kg)

The kilo-lab serves as an intermediate scale between laboratory glassware and pilot plant reactors. Equipment typically includes 10-50 liter jacketed glass or stainless steel reactors with overhead stirring, temperature control (heating/cooling jacket with recirculating thermostat), and metered addition capability.

Kilo-lab campaigns serve several purposes:

• Scale confirmation: Verify that reactions behave as expected at 10-100x laboratory scale
• Material generation: Produce sufficient quantities of intermediates and final product for downstream development activities (formulation, stability, analytical method validation)
• Process parameter refinement: Fine-tune addition rates, temperatures, stirring speeds, and workup procedures based on actual heat transfer and mixing performance at scale
• Impurity profiling: Generate sufficient impurity data at representative scale to support specification setting and regulatory submissions

Pilot Plant Operations (10-100 kg)

Pilot plant operations move chemistry into industrial-grade equipment: 100-1,000 liter stainless steel or glass-lined steel reactors with automated process control, precise temperature management (steam/hot water heating, chilled brine or glycol cooling), engineered ventilation, and integrated safety systems (rupture discs, relief valves, gas detection).

Key engineering considerations at pilot scale that do not exist at laboratory scale:

Parameter	Lab Scale (1 L)	Pilot Scale (500 L)	Impact
Surface-to-volume ratio	~30 cm2/mL	~0.6 cm2/mL	Heat transfer is 50x less efficient; cooling rates are dramatically slower
Mixing time to homogeneity	Seconds	Minutes	Reagent addition must be slow enough for mixing; local concentration gradients can form
Minimum jacket temperature differential	Not applicable	5-10 degrees C	Cannot achieve precise temperature control below this differential
Addition time for reagents	Minutes	Hours	Extended addition affects selectivity and impurity formation
Filtration time	Minutes	Hours	Product may degrade or transform during extended filtration
Cycle time per batch	Hours to 1 day	1-5 days per step	Production scheduling and facility utilization become critical

Telescoping Steps

One of the most impactful process optimizations at pilot scale is telescoping — combining multiple synthetic steps into a single operation by carrying the product of one reaction directly into the next without isolation and purification of the intermediate.

Telescoping offers significant advantages:

• Reduced cycle time: Eliminating intermediate isolation (filtration, drying, re-dissolution) can reduce per-step cycle time by 50-70%
• Improved yield: Each isolation step incurs yield losses (typically 5-15% per isolation). Telescoping two steps eliminates one set of losses.
• Reduced solvent consumption: Fewer workup and purification operations mean less solvent used and less waste generated
• Reduced operator exposure: Fewer material handling operations mean fewer opportunities for worker exposure to active intermediates

However, telescoping requires that impurities from the first reaction do not interfere with the second reaction and that the solvent system is compatible with both reactions. Successful telescoping is built on thorough understanding of impurity fate and careful solvent selection — both outcomes of Stage 2 optimization.

Example: Cost Impact of Pilot Plant Optimization

A concrete example illustrates the cumulative impact of process optimization at pilot scale. Consider a 6-step synthesis of a kinase inhibitor API:

Metric	Unoptimized (Med Chem Route)	After Stage 2 Optimization	After Pilot Optimization
Overall yield	8%	28%	35%
Step count (with isolations)	6 (6 isolations)	6 (6 isolations)	6 (3 isolations — 2 telescoped pairs + final)
Total solvent consumption per kg API	12,000 L	5,500 L	3,200 L
Pd catalyst cost per kg API	$18,000	$1,200	$900
Chromatographic purifications	3	0	0
Cycle time per batch (100 L reactor)	Not feasible	18 days	11 days
Estimated cost per kg API	Not feasible at scale	$8,500	$4,800
Annual cost at 200 kg/year	N/A	$1,700,000	$960,000

The combined savings from reaction optimization and pilot-scale process improvements are $740,000 per year for this single product — far exceeding the one-time development investment.

Timeline and Cost for Stage 4

Kilo-lab operations typically require 1-3 months and cost $50,000-$150,000 per campaign. Pilot plant operations require 2-6 months and cost $150,000-$500,000, depending on the number of steps, batch size, and whether cGMP compliance is required. Projects requiring cGMP pilot batches for clinical supply add approximately 30-50% to both timeline and cost due to enhanced documentation, quality oversight, and release testing requirements.

Stage 5: Technology Transfer Documentation and Validation Batches

The final stage prepares the process for commercial manufacturing by generating the documentation package that enables reliable technology transfer and executing validation batches that demonstrate process consistency.

Technology Transfer Documentation

A complete technology transfer package for a chemical process includes:

• Process Description: Step-by-step narrative describing each operation, including all parameters (temperatures, times, volumes, stoichiometries) with their proven acceptable ranges
• Master Batch Record: The manufacturing instruction document that operators will follow, specifying equipment, quantities, procedures, in-process controls, and acceptance criteria for each step
• Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs): Formal identification of which process parameters critically impact product quality, based on process development data and risk assessment
• In-Process Control (IPC) Strategy: Analytical methods and acceptance criteria applied during manufacturing to confirm that the process is performing within its design space before proceeding to the next step
• Analytical Methods and Validation: Complete documentation of all analytical methods used for raw material testing, in-process control, and final product release, including method validation reports per ICH Q2(R2)
• Raw Material Specifications: Specifications for all starting materials, reagents, solvents, and catalysts, including acceptable suppliers and incoming testing requirements
• Impurity Control Strategy: Documentation of how each specified impurity is controlled — whether through process control (upstream control), purification (downstream purge), or specification (acceptance in final product within defined limits), per ICH Q3A and ICH Q11 principles
• Process Safety Report: Summary of all safety assessments conducted during development, including thermal screening data, reaction calorimetry results, HAZOP action items, and engineering safeguards
• Development History Report: Narrative documenting the development rationale for key decisions — why this route was selected, why these conditions were chosen, what alternatives were considered and rejected. This document supports regulatory submissions and provides institutional knowledge for future process improvements

Validation Batches

Process validation demonstrates that the manufacturing process consistently produces material meeting its predetermined quality specifications when operated within its defined parameters. Per FDA Guidance on Process Validation (2011, updated) and ICH Q7, validation involves three stages:

Stage 1 — Process Design: Already completed through Stages 1-4 of this framework. The development data establishes the process design space and identifies CPPs and CQAs.

Stage 2 — Process Qualification: Execution of validation batches (minimum three consecutive successful batches, per ICH Q7 Section 12.5) at commercial scale, with enhanced sampling and testing to confirm that the process performs as designed. Key activities include:

• Execution of the process per the Master Batch Record with no deviations from defined parameters
• Enhanced in-process sampling at additional time points and locations to characterize process performance in detail
• Full release testing of each batch to confirm compliance with all specifications
• Statistical analysis of results across the three batches to demonstrate consistency

Stage 3 — Continued Process Verification: Ongoing monitoring of process performance during routine commercial manufacturing to detect trends, drift, or emerging variability that might indicate a loss of process control. This is an ongoing activity, not a one-time event.

Regulatory Filing Support

The documentation generated through Stage 5 feeds directly into CTD Module 3 (Quality) for regulatory submissions:

• 3.2.S.2.2 (Description of Manufacturing Process and Process Controls): Derived from the Process Description and Master Batch Record
• 3.2.S.2.3 (Control of Materials): Derived from Raw Material Specifications
• 3.2.S.2.4 (Controls of Critical Steps and Intermediates): Derived from the CPP/CQA analysis and IPC Strategy
• 3.2.S.2.6 (Manufacturing Process Development): Derived from the Development History Report
• 3.2.S.3.2 (Impurities): Derived from the Impurity Control Strategy
• 3.2.S.4 (Control of Drug Substance): Derived from the final product specification and validated analytical methods

Organizations that build their technology transfer documentation with regulatory filing requirements in mind — using the CTD structure as a template — avoid the costly and time-consuming exercise of retroactively reorganizing development data into regulatory format.

Timeline and Cost for Stage 5

Technology transfer documentation requires 1-3 months and costs $30,000-$100,000, primarily driven by technical writing and document review labor. Validation batches (three batches at pilot or commercial scale) require 2-4 months and cost $200,000-$800,000 depending on batch size, analytical testing scope, and the cost of raw materials consumed. The total Stage 5 investment of $230,000-$900,000 is the final expenditure before commercial manufacturing begins.

Total Investment Summary: Lab Bench to Pilot Plant

Stage	Duration	Cost Range	Key Deliverables
1. Route selection and retrosynthetic analysis	2-6 weeks	$15,000-$50,000	Route scoring report, recommended lead route, starting material assessment
2. Reaction optimization (DoE, solvent/catalyst screening)	2-4 months	$80,000-$250,000	Optimized conditions for each step, DoE models, preliminary process description
3. Process safety assessment	4-8 weeks	$30,000-$100,000	DSC/ARC data, RC1 results, HAZOP report, safety-qualified process
4. Pilot plant design and execution	3-9 months	$200,000-$650,000	Pilot-scale batch data, refined process parameters, production-scale material
5. Tech transfer documentation and validation	3-7 months	$230,000-$900,000	Complete tech transfer package, validation report, regulatory-ready documentation
Total	10-24 months	$555,000-$1,950,000	Manufacturing-ready, validated, documented process

These ranges cover the majority of pharmaceutical and specialty chemical applications. Projects at the lower end involve shorter synthetic sequences (3-4 steps) with well-precedented chemistry. Projects at the upper end involve complex multi-step syntheses (8-12 steps) with hazardous chemistry, asymmetric catalysis, or potent compound handling requirements.

Choosing a Process Chemistry Partner

The process chemistry optimization journey described in this guide can be executed internally, through an external partner, or through a hybrid approach. For most organizations — particularly those without established process chemistry and pilot plant infrastructure — partnering with a specialized process development organization is the most efficient and lowest-risk approach.

Key selection criteria for a process chemistry partner:

• Integrated capabilities across all five stages: Partners who can execute route selection through validation in a single organization eliminate technology transfer risk and preserve institutional knowledge. Understanding the CRO vs CDMO decision helps you select the right partner model for each stage.
• Experienced process chemists: PhD-level chemists with specific training and track record in process development, not just medicinal or academic synthesis
• DoE and statistical analysis capability: Modern process optimization requires computational tools and statistical expertise, not just empirical chemistry
• Process safety infrastructure: In-house DSC, ARC, RC1 capability, and experience conducting HAZOPs
• Pilot plant facilities: Equipped kilo-lab and pilot plant with appropriate reactor sizes, temperature control, and safety systems
• Quality systems: cGMP-compliant quality systems for projects requiring clinical trial material or regulatory filing support
• Regulatory filing experience: Familiarity with CTD Module 3 requirements and experience supporting IND, NDA, and ANDA submissions

Frequently Asked Questions

How much does process chemistry optimization cost from lab to pilot?

Total investment across all five stages typically ranges from $555,000 to $1,950,000 over 10-24 months. Route selection costs $15,000-$50,000, reaction optimization runs $80,000-$250,000, safety assessment adds $30,000-$100,000, pilot plant execution costs $200,000-$650,000, and tech transfer with validation batches requires $230,000-$900,000. Simpler 3-4 step syntheses fall at the lower end.

Why can’t I just scale up the medicinal chemistry route directly?

Medicinal chemistry routes prioritize speed and flexibility, not manufacturing efficiency. They frequently use expensive catalysts at high loadings (5-10 mol% palladium), require chromatographic purification, employ problematic solvents, and tolerate low yields. Scaling these routes directly can cost 10-40x more per gram than an optimized process, and can create serious safety hazards from uncontrolled exothermic reactions at large scale.

What is Design of Experiments (DoE) and why is it important for process optimization?

DoE is a statistical methodology that systematically varies multiple process parameters simultaneously to identify optimal conditions with minimum experiments. Unlike one-variable-at-a-time approaches, DoE reveals interaction effects between parameters and generates mathematical models that predict performance across the entire parameter space. A DoE campaign for a single reaction step typically requires 2-4 weeks and 30-60 experiments.

How long does a pilot plant campaign typically take?

Kilo-lab operations (1-10 kg scale) require 1-3 months. Pilot plant operations (10-100 kg scale) require 2-6 months, depending on step count, batch size, and cGMP requirements. Projects requiring cGMP pilot batches for clinical supply add approximately 30-50% to both timeline and cost due to enhanced documentation and quality oversight.

What is telescoping and how does it reduce manufacturing costs?

Telescoping combines multiple synthetic steps into a single operation by carrying the product of one reaction directly into the next without intermediate isolation. This reduces cycle time by 50-70% per telescoped pair, eliminates 5-15% yield losses per isolation step, reduces solvent consumption, and minimizes operator exposure. Successful telescoping requires thorough understanding of impurity fate and compatible solvent systems.

Why ChemContract for Process Chemistry Optimization

ChemContract provides integrated process chemistry optimization services spanning all five stages — from initial route evaluation through validated pilot-plant production — within a single U.S.-based organization.

• Experienced process chemistry team: Our scientists have deep expertise in route selection, reaction optimization using DoE methodology, and the translation of laboratory chemistry into manufacturing-ready processes
• Complete safety assessment capability: In-house DSC, ARC, and reaction calorimetry (RC1) instrumentation, with experienced safety engineers who conduct HAZOPs and design appropriate engineering safeguards
• Scalable facilities: Laboratory, kilo-lab, and pilot plant equipment supporting seamless progression from gram-scale development through multi-kilogram production campaigns
• Regulatory documentation expertise: Our technical writing team prepares technology transfer packages and CTD Module 3 documentation that meet FDA and EMA expectations, reducing the time and cost of regulatory submissions
• cGMP compliance: Quality systems supporting GMP manufacturing for clinical trial material supply and commercial production
• Single-partner continuity: The process chemists who optimize your route are the same scientists who execute your pilot campaign and prepare your technology transfer documentation — eliminating the information loss and delays inherent in multi-vendor development strategies

From the first retrosynthetic analysis to the final validation batch, ChemContract delivers process chemistry optimization that transforms laboratory discoveries into commercially viable manufacturing processes — on time, within budget, and with the documentation rigor that regulators expect. Contact our process chemistry team to discuss your scale-up project, or explore how our contract R&D services accelerate development timelines.